Genetics Generation Advancement Past Earnings Performance
Past criteria checks 5/6
Genetics Generation Advancement has been growing earnings at an average annual rate of 45%, while the Biotechs industry saw earnings growing at 21.4% annually. Revenues have been growing at an average rate of 8.9% per year. Genetics Generation Advancement's return on equity is 10.2%, and it has net margins of 8.8%.
Key information
45.0%
Earnings growth rate
45.0%
EPS growth rate
| Biotechs Industry Growth | 12.2% |
| Revenue growth rate | 8.9% |
| Return on equity | 10.2% |
| Net Margin | 8.8% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Revenue & Expenses Breakdown
How Genetics Generation Advancement makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 664 | 58 | 169 | 58 |
| 30 Jun 24 | 649 | 44 | 171 | 58 |
| 31 Mar 24 | 625 | 35 | 168 | 55 |
| 31 Dec 23 | 593 | 29 | 164 | 54 |
| 30 Sep 23 | 576 | 28 | 162 | 54 |
| 30 Jun 23 | 554 | 31 | 157 | 52 |
| 31 Mar 23 | 543 | 22 | 155 | 52 |
| 31 Dec 22 | 548 | 26 | 154 | 52 |
| 30 Sep 22 | 528 | 18 | 150 | 54 |
| 30 Jun 22 | 532 | 14 | 147 | 55 |
| 31 Mar 22 | 539 | 19 | 148 | 56 |
| 31 Dec 21 | 520 | 8 | 149 | 51 |
| 30 Sep 21 | 513 | 0 | 147 | 45 |
| 30 Jun 21 | 495 | -8 | 143 | 39 |
| 31 Mar 21 | 457 | -16 | 137 | 33 |
| 31 Dec 20 | 443 | -16 | 131 | 32 |
| 30 Sep 20 | 441 | -5 | 131 | 34 |
| 30 Jun 20 | 426 | -1 | 129 | 34 |
| 31 Mar 20 | 439 | 10 | 130 | 33 |
| 31 Dec 19 | 429 | 18 | 127 | 30 |
| 30 Sep 19 | 424 | 20 | 125 | 24 |
| 30 Jun 19 | 408 | 21 | 123 | 21 |
| 31 Mar 19 | 385 | 16 | 118 | 20 |
| 31 Dec 18 | 382 | 17 | 117 | 20 |
| 30 Sep 18 | 372 | 14 | 107 | 24 |
| 30 Jun 18 | 373 | 17 | 104 | 22 |
| 31 Mar 18 | 369 | 14 | 99 | 20 |
| 31 Dec 17 | 366 | 11 | 94 | 20 |
| 30 Sep 17 | 352 | 4 | 93 | 16 |
| 30 Jun 17 | 368 | 2 | 89 | 15 |
| 31 Mar 17 | 360 | -2 | 88 | 15 |
| 31 Dec 16 | 346 | -8 | 88 | 14 |
| 30 Sep 16 | 333 | -11 | 85 | 15 |
| 30 Jun 16 | 297 | -16 | 82 | 16 |
| 31 Mar 16 | 299 | -9 | 77 | 19 |
| 31 Dec 15 | 275 | -13 | 76 | 22 |
| 30 Sep 15 | 262 | -36 | 76 | 24 |
| 30 Jun 15 | 225 | -40 | 75 | 24 |
| 31 Mar 15 | 214 | -47 | 76 | 24 |
| 31 Dec 14 | 222 | -42 | 72 | 22 |
| 30 Sep 14 | 236 | -15 | 74 | 20 |
| 30 Jun 14 | 259 | -17 | 72 | 19 |
| 31 Mar 14 | 243 | -22 | 72 | 18 |
| 31 Dec 13 | 236 | -33 | 73 | 18 |
Quality Earnings: 4160 has high quality earnings.
Growing Profit Margin: 4160's current net profit margins (8.8%) are higher than last year (4.9%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 4160's earnings have grown significantly by 45% per year over the past 5 years.
Accelerating Growth: 4160's earnings growth over the past year (109%) exceeds its 5-year average (45% per year).
Earnings vs Industry: 4160 earnings growth over the past year (109%) exceeded the Biotechs industry 8.8%.
Return on Equity
High ROE: 4160's Return on Equity (10.2%) is considered low.